<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of allergic bronchopulmonary aspergillosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of allergic bronchopulmonary aspergillosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of allergic bronchopulmonary aspergillosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Praveen Akuthota, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1410587725"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction that occurs in response to colonization of the airways with <em>Aspergillus fumigatus</em> and almost exclusively in patients with asthma or cystic fibrosis (CF) [<a href="#rid1">1-4</a>]. In some cases, repeated episodes of bronchial obstruction, inflammation, and mucoid impaction can lead to bronchiectasis, fibrosis, and respiratory compromise [<a href="#rid5">5</a>].</p><p>The treatment and prognosis of ABPA will be reviewed here. The clinical manifestations and diagnosis of ABPA and general issues related to the management of asthma and bronchiectasis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2419.html" rel="external">"Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis"</a> and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/1435.html" rel="external">"Bronchiectasis in adults: Treatment of acute and recurrent exacerbations"</a> and  <a class="medical medical_review" href="/z/d/html/6355.html" rel="external">"Bronchiectasis in children without cystic fibrosis: Management"</a>.)</p><p class="headingAnchor" id="H1410588617"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment of allergic bronchopulmonary aspergillosis (ABPA) aims to control episodes of acute inflammation and to limit progressive lung injury. The roles of systemic glucocorticoids and antifungal agents vary with the disease activity. Antifungal therapy may help to decrease exacerbations. Inhaled glucocorticoids may help control symptoms of asthma but do not have documented efficacy in preventing acute episodes of ABPA.</p><p class="headingAnchor" id="H1410588640"><span class="h2">Acute ABPA</span><span class="headingEndMark"> — </span>For acute ABPA manifest by radiographic opacities (usually upper or middle lobes) and an elevated total serum IgE (generally &gt;1000 international units/mL), systemic glucocorticoids are the mainstay of treatment [<a href="#rid6">6-9</a>]. In addition, the 2016 Infectious Diseases Society of America (IDSA) guidelines on the treatment of aspergillosis recommend that therapy of acute or recurrent ABPA should consist of a combination of glucocorticoids and <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> [<a href="#rid10">10</a>]. <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">Voriconazole</a> is a reasonable alternative to itraconazole because it is better tolerated in some patients and is well absorbed.</p><p class="headingAnchor" id="H1410588722"><span class="h3">Systemic glucocorticoids</span><span class="headingEndMark"> — </span>Systemic glucocorticoids are considered the mainstay of treatment of acute ABPA based on the results of case series; no clinical trials have been performed. As an example, a case series of 84 patients found no patients who failed to respond to a course of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> with clearing of radiographic opacities, a decline of &gt;50 percent in total IgE, and a return of blood eosinophil counts to normal [<a href="#rid11">11</a>]. In a separate series, 126 patients with a new diagnosis of ABPA all responded to a course of oral glucocorticoids with development of remission (decline in IgE levels &gt;35 percent and clearance of chest radiographic lesions) by six weeks [<a href="#rid12">12</a>].</p><p>The optimal dosing of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> is not known [<a href="#rid1">1,12,13</a>]. One commonly used regimen is an initial dose of prednisone 0.5 mg/kg daily (or equivalent) for 14 days, followed by conversion to an every other day regimen of 0.5 mg/kg, and further tapering and discontinuation at three months [<a href="#rid1">1</a>]. Some patients may need a higher initial dose of prednisone (eg, 40 to 60 mg/day), if they are having an acute asthma flare. In an unblinded, randomized trial that included 92 patients, prednisolone 0.5 mg/kg per day for two weeks, then tapering to 0.5 mg/kg on alternate days, then further gradual tapering, was compared with prednisolone 0.75 mg/kg per day for six weeks followed by a more gradual taper [<a href="#rid13">13</a>]. No significant difference was noted in the number of patients with an exacerbation in the first year or in the proportion of patients who remained glucocorticoid-dependent after two years. The rate of adverse effects was greater in the high dose glucocorticoid group.</p><p>Total serum IgE levels decrease by approximately 25 percent after one month of treatment and 60 percent after two months [<a href="#rid14">14</a>]. A decrease of 35 percent is considered a good therapeutic response, such that tapering of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> is appropriate.</p><p>Glucocorticoids are associated with significant immunosuppressive and metabolic side effects that are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H1410588810"><span class="h3">Antifungal therapy</span><span class="headingEndMark"> — </span>We reserve antifungal therapy with <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> for patients who are unable to taper oral glucocorticoids or have an exacerbation of ABPA. Our approach differs from the approach advocated by the Infectious Diseases Society of America, which recommends itraconazole as part of initial therapy for acute ABPA, with the goal of enabling a reduction in the long-term glucocorticoid dose [<a href="#rid10">10,15,16</a>]. The duration of antifungal therapy was 16 weeks in the two randomized trials [<a href="#rid17">17,18</a>], but some reports suggest that a longer duration may be necessary (eg, three to six months or longer) [<a href="#rid5">5,19,20</a>]. Relapse after discontinuation is common, and longer-term suppressive therapy may be necessary. However, the risks of adverse effects (eg, hepatotoxicity, nausea) and interactions with glucocorticoid metabolism have limited the widespread use of antifungal agents in ABPA.</p><p>Two randomized trials, a retrospective cohort study, and a small prospective study have demonstrated the utility of <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> in addition to glucocorticoids for the therapy of ABPA [<a href="#rid15">15,17,18,21,22</a>]. The larger of the randomized trials compared itraconazole with placebo in 55 patients already receiving glucocorticoids [<a href="#rid17">17</a>]. The addition of itraconazole for 16 weeks was associated with a significant increase in the likelihood of a clinical response (46 versus 19 percent). A response was defined as a reduction of at least 50 percent in the glucocorticoid dose, a decrease of at least 25 percent in the serum IgE concentration, and one of the following: an improvement of at least 25 percent in exercise tolerance or pulmonary function tests, or partial or complete resolution of pulmonary infiltrates. Adverse effects were similar in both groups. While total IgE decreases with therapy, specific IgE antibodies against <em>A. fumigatus</em> may not [<a href="#rid22">22</a>].</p><p>While oral glucocorticoids were used in addition to <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> in the above studies [<a href="#rid17">17,21,22</a>], a separate randomized, open-label trial in 131 patients with acute ABPA and asthma compared itraconazole 200 mg twice daily with <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> (0.5 mg/kg per day for four weeks, 0.25 mg/kg per day for four weeks, then progressively tapered and discontinued at four months) as initial therapy [<a href="#rid23">23</a>]. The number of patients with an exacerbation at one and two years, the time to first exacerbation, and the percent decline in total serum IgE were not different between the groups. Methodologic concerns, such as eight patients switching from itraconazole to prednisolone after failure to respond at six weeks and loss to follow up at two years, limit the strength of the conclusions.</p><p><a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a> is thought to work by reducing the antigenic stimulus for bronchial inflammation [<a href="#rid10">10</a>]. The antifungal effects can be inferred by the ability of itraconazole to reduce specific <em>Aspergillus</em> IgG [<a href="#rid18">18</a>]. Another possible contributor to itraconazole action in ABPA is by impairing metabolism of the glucocorticoid, thereby raising plasma levels. This effect is best described with <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> but may not be important with <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>, which is the active form of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> [<a href="#rid24">24,25</a>]. The development of Cushing's syndrome has been recognized in ABPA patients treated with itraconazole and glucocorticoids, with most case reports involving inhaled glucocorticoids [<a href="#rid26">26-28</a>]. Such patients are also at risk for adrenal insufficiency due to inhibition of cortisol synthesis, which becomes apparent with glucocorticoid dose reduction [<a href="#rid28">28-30</a>]. <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">Voriconazole</a> has a similar effect through inhibition of CYP3A4.</p><p>Many clinicians no longer use <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> for invasive forms of pulmonary aspergillosis and use <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> instead. Successful use of voriconazole in ABPA has been reported in a case series and a small, unblinded randomized trial [<a href="#rid31">31-34</a>]. Whether voriconazole is superior to itraconazole in ABPA remains unknown, although voriconazole has distinct advantages to itraconazole, such as improved gastrointestinal tolerance and bioavailability. The same case series suggests that the newer azole agent, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, may be effective for ABPA as well [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/2440.html" rel="external">"Chronic pulmonary aspergillosis: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a> – The oral itraconazole regimen in adults includes a loading dose of 200 mg three times a day for three days, followed by 200 mg twice daily for 16 weeks. Children should receive 5 mg/kg per day given either once a day or, if the total dose exceeds 200 mg/day, given in divided twice daily doses with food. Liver function tests should be monitored closely for evidence of hepatotoxicity. It is recommended that itraconazole serum concentrations be obtained to ensure appropriate absorption of the drug. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Hepatotoxicity'</a> and  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Itraconazole'</a> and  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Serum drug concentration monitoring'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a> capsules should be taken with food. The liquid formulation of itraconazole, given in the same doses noted above, overcomes problems caused by poor absorption of the capsule and achieves approximately 30 percent higher concentrations in the serum at the same dose. The solution should be given on an empty stomach to achieve the highest serum concentrations. However, more gastrointestinal upset occurs with the solution formulation, which precludes its use in some patients.</p><p></p><p class="bulletIndent1">Acid-blocking drugs should be avoided when the capsule formulation is given.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">Voriconazole</a> — Oral voriconazole dosing for adults includes a loading dose of 400 mg every 12 hours for two doses, followed by a maintenance dose of 200 mg twice daily for 16 weeks. Liver function tests should be monitored closely for any evidence of hepatotoxicity. Voriconazole levels should be measured after about five days of therapy to ensure adequate absorption and avoid toxicity. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Hepatotoxicity'</a> and  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Serum drug concentration monitoring'</a>.)</p><p></p><p class="bulletIndent1">The dosing of oral <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> in children is discussed separately. (See  <a class="drug drug_pediatric" href="/z/d/drug information/12885.html" rel="external">"Voriconazole: Pediatric drug information"</a>.)</p><p></p><p class="headingAnchor" id="H1410589325"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>The clinical response to glucocorticoids should be monitored with serial measurement of the serum total IgE concentration every one to two months [<a href="#rid35">35</a>]. Resolution of radiographic opacities and clinical improvement are generally accompanied by at least a 35 percent reduction in serum total IgE [<a href="#rid4">4</a>]. However, patients with a baseline IgE level &lt;2500 international units/mL (&lt;6000 ng/mL) may not have as large of a percentage decrease in IgE in response to glucocorticoids [<a href="#rid36">36</a>]. A doubling in total IgE is generally associated with evidence of an exacerbation of ABPA [<a href="#rid12">12</a>].</p><p>We do not monitor <em>Aspergillus</em> specific IgE or IgG due to a lack of correlation with clinical response [<a href="#rid12">12,37</a>].</p><p class="headingAnchor" id="H1410589413"><span class="h2">ABPA in remission</span><span class="headingEndMark"> — </span>Remission of ABPA is characterized by a normal or mildly elevated serum total IgE and absence of radiographic opacities in a patient who has been off systemic glucocorticoids for longer than six months. Inhaled glucocorticoids are continued to maintain asthma control as per current guidelines. ABPA is monitored by serum total IgE levels every three to six months. An increase in serum IgE may herald or accompany lung opacities on imaging studies and peripheral blood eosinophilia [<a href="#rid35">35,38</a>]. Spirometry is performed annually and in response to changes in symptoms. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a>.)</p><p>Antifungal therapy is not used to prevent exacerbations given potential toxicity and lack of proven benefit.</p><p class="headingAnchor" id="H1410589457"><span class="h2">ABPA exacerbation</span><span class="headingEndMark"> — </span>Exacerbations or flares (stage III) are frequent and are accompanied by at least a 100 percent rise in serum total IgE over baseline [<a href="#rid1">1</a>]. Twenty to 35 percent of flares are asymptomatic and are detected radiographically and serologically. Chest radiographs should be obtained if signs of an asymptomatic flare are detected during physical examination or if a patient has an established pattern of recurrent, asymptomatic flares. Doses of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> and inhaled glucocorticoids that are sufficient to control asthma may be insufficient to prevent exacerbations of ABPA, thus the need for monitoring total IgE to gauge control of ABPA [<a href="#rid11">11</a>].</p><p>For treatment, we suggest a tapered glucocorticoid regimen, as detailed above for acute onset disease. An antifungal agent may be added, also similar to the use in acute onset ABPA. (See <a class="local">'Systemic glucocorticoids'</a> above and <a class="local">'Antifungal therapy'</a> above.)</p><p class="headingAnchor" id="H92057609"><span class="h2">Use of biologic agents in ABPA</span><span class="headingEndMark"> — </span>The optimal treatment of patients who have recurrent exacerbations or are unable to taper off of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> without a flare of ABPA is not known.</p><p>Our practice is to use asthma biologics in patients with ABPA and recurrent exacerbations or inability to taper off oral glucocorticoids despite a course of antifungal therapy and optimal inhaled therapy for asthma, particularly those with asthma as a predisposing condition. In general, we start with one of the anti-interleukin (IL)-5 agents (eg, <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a>, <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>) due to their favorable safety profile and less frequent dosing intervals.</p><p>Other options include <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> (anti-immunoglobulin [Ig]E) and <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> (anti-IL-4 subunit antibody). Like <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> and <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>, these agents target one of the allergic mechanisms that are upregulated in ABPA. Each has been shown to improve outcomes in case series of patients with ABPA and are approved for the treatment of severe asthma.</p><p>While awaiting long-term studies of efficacy and safety in ABPA, we suggest addition of a biologic agent based upon on the eligibility criteria for asthma  (<a class="graphic graphic_table graphicRef118483" href="/z/d/graphic/118483.html" rel="external">table 1</a>), which include age, weight, total serum IgE, and blood eosinophil counts. It should be noted that because all patients with ABPA will have an elevated IgE level and most will have an elevated eosinophil count, they will have biomarkers that support the use of one or more of the approved biologic agents.</p><p class="headingAnchor" id="H1410589506"><span class="h3">Anti-IgE therapy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">Omalizumab</a>, a humanized monoclonal antibody against IgE, may be beneficial in the treatment of ABPA in the setting of poorly-controlled asthma. A benefit to omalizumab is suggested by systematic reviews of omalizumab [<a href="#rid39">39,40</a>] and by the studies outlined below. For asthma, the dosing of omalizumab follows a nomogram based on weight and total serum IgE level. However, the nomogram is more difficult to apply in ABPA due to high serum levels of IgE (ie, above the upper limit of nomogram-based dosing). Based on clinical experience and limited published data, we typically administer omalizumab 375 mg, subcutaneously, every 14 days in patients with ABPA [<a href="#rid39">39,41-43</a>]. Proof of efficacy in ABPA for patients with and without cystic fibrosis (CF) awaits more definitive clinical trials. (See  <a class="medical medical_review" href="/z/d/html/545.html" rel="external">"Anti-IgE therapy", section on 'Administration'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>The effect of <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> was examined in 13 patients with ABPA and poorly-controlled asthma (mean total IgE 2314 ± 2125 international units/mL) who were randomly assigned to omalizumab 750 mg subcutaneously or placebo once a month for four months, followed by a three month washout phase, and then cross-over to the opposite treatment group [<a href="#rid41">41</a>]. Other asthma treatments remained constant through the trial. During the active treatment phases, exacerbations were significantly less frequent with omalizumab (2 versus 12 events).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an open-label study that included 16 adult ABPA patients without CF, use of <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> for one year was associated with a marked decrease in the number of asthma exacerbations and in oral glucocorticoid dose compared with the year prior to starting omalizumab [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In eight case reports, 13 children with CF and ABPA received <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> at doses ranging from 300 to 450 mg every two to four weeks, resulting in improved forced expiratory volume in one second (FEV<sub>1</sub>), fewer respiratory symptoms, and decreased glucocorticoid use in most, but not all, patients [<a href="#rid45">45</a>].</p><p></p><p>A systematic review that included one study of <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> in 14 patients with cystic fibrosis and ABPA concluded that the evidence was insufficient to determine benefit in this setting [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H3272189086"><span class="h3">Anti-interleukin-5 agents</span><span class="headingEndMark"> — </span>Two anti-interleukin (IL)-5 agents have been assessed in observational studies of patients with ABPA: <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> (anti-IL-5) and <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a> (anti-IL-5 receptor alpha [IL-5R]) [<a href="#rid47">47-52</a>]. We typically add one of these agents in patients with ABPA who meet criteria for severe asthma and have a blood eosinophil count ≥300/microL. Dosing of anti-IL-5/5R agents in severe asthma is described separately  (<a class="graphic graphic_table graphicRef118483" href="/z/d/graphic/118483.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Anti-IL-5 therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 20 patients with ABPA and severe asthma, addition of <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> 100 mg every four weeks for six months was associated with a decrease in the annualized number of exacerbations (3 to 0), reduction in the dose of systemic glucocorticoids needed for asthma control, and improvement in asthma symptom scores compared with the year prior to mepolizumab [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A separate study of patients with severe asthma and fungal sensitization included nine patients with ABPA, three of whom had failed treatment with <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> and two of whom had discontinued azole therapy due to adverse effects, who were treated with anti-IL-5 agents [<a href="#rid53">53</a>]. During 48 weeks of treatment with either <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> or <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>, exacerbations in the subgroup of patients with ABPA decreased compared with the prior year, asthma related quality of life improved, and requirement for oral glucocorticoids decreased.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A literature review described eight previously reported cases of ABPA in which asthma control and radiographic evidence of mucus plugging improved with <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> [<a href="#rid51">51</a>]. Half of the patients had a significant decrease in total IgE. A separate case report described a patient with glucocorticoid-dependent ABPA (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> ≥20 mg daily) despite conventional asthma therapies, courses of <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> and <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, and ongoing therapy with <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> who was able to discontinue oral glucocorticoids after addition of mepolizumab [<a href="#rid47">47</a>].</p><p></p><p>Further study is needed to determine the appropriate role of anti-IL-5/5R agents in the treatment of ABPA and whether these agents interrupt progression of bronchiectasis.</p><p class="headingAnchor" id="H1157415136"><span class="h3">Anti-IL-4 receptor alpha subunit antibody</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">Dupilumab</a> is a monoclonal antibody that binds to the alpha subunit of the IL-4 receptor and is approved for the treatment of moderate-to-severe, eosinophilic asthma (eg, peripheral blood eosinophils ≥150/microL) in patients age 12 years and older. In case reports of patients with ABPA, addition of dupilumab was associated with successful tapering of oral glucocorticoid [<a href="#rid54">54,55</a>]. A multi-center randomized clinical trial testing the efficacy of dupilumab in ABPA (with asthma as the predisposing condition) is currently underway.</p><p>The dosing and administration of <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> in severe asthma are described separately. (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Anti-lL-4 receptor alpha subunit antibody (dupilumab)'</a>.)</p><p class="headingAnchor" id="H1410589584"><span class="h2">Fibrotic lung disease</span><span class="headingEndMark"> — </span>Fibrotic lung disease due to ABPA is characterized by impaired respiratory function and chronic scarring on imaging studies. Laboratory studies in one case series revealed serum Aspergillus specific IgE and IgG levels that were elevated compared with a control pool of serum samples from patients with asthma but not ABPA [<a href="#rid56">56</a>]. Patients with fibrotic lung disease may require long-term <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for control of asthma. Patients with a FEV<sub>1</sub> of 0.8 L or less (after initial glucocorticoid treatment) tend to have a poor prognosis.</p><p class="headingAnchor" id="H1410589724"><span class="h2">Patients with cystic fibrosis</span><span class="headingEndMark"> — </span>Treatment of acute ABPA in CF mirrors that described above for patients without cystic fibrosis, although this has not been studied in prospective trials [<a href="#rid5">5,57</a>]. Systemic glucocorticoids are used as in ABPA with asthma, and therapy should result in a reduction in IgE level. Clinical trial data for the use of antifungal therapy to treat ABPA in patients with CF are lacking, but observational data are supportive [<a href="#rid58">58</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> (tapering dosing for 18 days) and <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> (guided by serum trough levels for at least 12 months) were administered to 65 patients with CF and ABPA in an observational study [<a href="#rid20">20</a>]. Serial lung function measurements demonstrated near return in FEV<sub>1</sub> to pre-ABPA levels by three months. Additionally, FEV<sub>1</sub> values over a median of 4.8 years after the ABPA diagnosis were comparable to those of 127 patients with CF without ABPA. In previous studies, ABPA was associated with accelerated loss of lung function [<a href="#rid59">59,60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one retrospective series of 16 patients with CF and ABPA, the use of <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> was associated with a 47 percent reduction in average daily glucocorticoid dose and a 55 percent reduction in the number of acute ABPA episodes [<a href="#rid59">59</a>].</p><p></p><p>Case reports and small case series have also described benefit from <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> in the long-term management of patients with CF and ABPA [<a href="#rid45">45,61,62</a>]. (See <a class="local">'Anti-IgE therapy'</a> above.)</p><p class="headingAnchor" id="H3160409084"><span class="h2">Other interventions</span><span class="headingEndMark"> — </span>The role of reducing exposure to environmental sources of <em>Aspergillus</em> has not been formally studied, but it seems prudent for patients to avoid high levels of Aspergillus exposure at home and at work [<a href="#rid1">1,63-66</a>].</p><p>Whether nebulized amphotericin is effective at reducing exacerbations is unclear. In a trial of 174 patients with ABPA, six months of nebulized liposomal amphotericin (25 mg once weekly) versus placebo resulted in a similar proportion of patients experiencing a severe exacerbation within 24 months (50.7 versus 51.3 percent) [<a href="#rid67">67</a>]. However, the extended median time-to-first event (337 versus 177 days) and fall in aspergillus markers during amphotericin treatment suggest the potential for benefit while on active therapy. In contrast, a previous observational study in 21 patients with ABPA suggested that nebulized amphotericin B (10 mg twice daily three times a week) may reduce ABPA symptoms and exacerbations [<a href="#rid68">68</a>]. Further study is needed to determine the clinical role for nebulized amphotericin therapy.</p><p>Immunotherapy with fungal allergens has not been evaluated in high-quality studies. Evidence to support the initiation of fungal immunotherapy for the treatment of ABPA is lacking, although patients already receiving immunotherapy for the treatment of other allergic disorders may safely continue it [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H1410589890"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The natural history, progression, remission, and recurrences of allergic bronchopulmonary aspergillosis (ABPA) are not well understood [<a href="#rid69">69</a>]. Patients without central bronchiectasis at the time of diagnosis tend to maintain their lung function despite occasional exacerbations. In an observational study, 55 patients with a diagnosis of ABPA, but normal high resolution computed tomography, were followed for 2 to 6.5 years [<a href="#rid70">70</a>]. Sixteen experienced exacerbations and six remained glucocorticoid dependent. The mean forced expiratory volume in one second improved, and none developed central bronchiectasis. One the other hand, rare patients have presented with pulmonary fibrosis despite few preceding episodes or symptoms [<a href="#rid3">3,5,56</a>].</p><p class="headingAnchor" id="H410889930"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109727.html" rel="external">"Society guideline links: Aspergillosis"</a>.)</p><p class="headingAnchor" id="H1410589924"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83427.html" rel="external">"Patient education: Allergic bronchopulmonary aspergillosis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1410589957"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment goals</strong> – Treatment of allergic bronchopulmonary aspergillosis (ABPA) aims to control episodes of acute inflammation and to limit progressive lung injury. The general teaching is that early treatment is important to try to prevent the development of bronchiectasis or pulmonary fibrosis. (See <a class="local">'Treatment'</a> above and <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic glucocorticoids</strong> – For patients with an acute flare or recurrent exacerbation of ABPA, we recommend systemic glucocorticoid therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The usual initial dose is <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 0.5 mg/kg (or equivalent) daily for 14 days followed by conversion to an every other day regimen and a slow taper over three to six months. An exception to this initial dose is the patient with a concomitant asthma exacerbation that requires a higher initial dose. (See <a class="local">'Systemic glucocorticoids'</a> above and <a class="local">'ABPA exacerbation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifungal therapy</strong> – We suggest antifungal therapy with <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> for patients who are unable to taper oral glucocorticoids or have an exacerbation of ABPA (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Alternatively, antifungal therapy can be given to all patients with acute ABPA with the goal of enabling a reduction in the long-term glucocorticoid dose. Antifungal therapy is typically continued for 16 weeks. (See <a class="local">'Acute ABPA'</a> above and <a class="local">'ABPA exacerbation'</a> above and  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Systemic glucocorticoids'</a> and  <a class="medical medical_review" href="/z/d/html/528.html" rel="external">"Acute exacerbations of asthma in adults: Home and office management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biologic agents for severe asthma</strong> – For patients with ABPA with recurrent exacerbations or inability to taper off oral glucocorticoids despite a course of antifungal therapy and optimal inhaled therapy for asthma, we suggest addition of a biologic agent (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The biologic agents <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>, <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a>, <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>, and <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> have improved outcomes in case series, but data are limited. Eligibility criteria for the individual biologic agents in severe asthma include age, weight, total serum IgE, and blood eosinophil count and are listed in the table  (<a class="graphic graphic_table graphicRef118483" href="/z/d/graphic/118483.html" rel="external">table 1</a>). (See <a class="local">'Use of biologic agents in ABPA'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled glucocorticoids</strong> – Patients with ABPA in remission may need inhaled glucocorticoids to maintain asthma control, possibly with long-acting beta-agonists, to control the underlying asthma. However, inhaled glucocorticoids do not have documented efficacy in preventing acute episodes of ABPA. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ABPA in cystic fibrosis</strong> – Treatment of acute ABPA in cystic fibrosis mirrors that described above for patients without cystic fibrosis, although this has not been studied in prospective trials. (See <a class="local">'Patients with cystic fibrosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspergillus exposure</strong> – The role of reducing exposure to environmental sources of <em>Aspergillus</em> has not been formally studied, but it seems prudent for patients to avoid high levels of Aspergillus exposure at home and at work. (See <a class="local">'Other interventions'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110:685.</a></li><li><a class="nounderline abstract_t">Zander DS. Allergic bronchopulmonary aspergillosis: an overview. Arch Pathol Lab Med 2005; 129:924.</a></li><li><a class="nounderline abstract_t">Tillie-Leblond I, Tonnel AB. Allergic bronchopulmonary aspergillosis. Allergy 2005; 60:1004.</a></li><li><a class="nounderline abstract_t">Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009; 135:805.</a></li><li><a class="nounderline abstract_t">Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37 Suppl 3:S225.</a></li><li><a class="nounderline abstract_t">Greenberger PA, Patterson R. Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma. J Allergy Clin Immunol 1988; 81:646.</a></li><li><a class="nounderline abstract_t">McCarthy DS, Pepys J. Allergic broncho-pulmonary aspergillosis. Clinical immunology. 2. Skin, nasal and bronchial tests. Clin Allergy 1971; 1:415.</a></li><li><a class="nounderline abstract_t">Breslin AB, Jenkins CR. Experience with allergic bronchopulmonary aspergillosis: some unusual features. Clin Allergy 1984; 14:21.</a></li><li><a class="nounderline abstract_t">Golbert TM, Patterson R. Pulmonary allergic aspergillosis. Ann Intern Med 1970; 72:395.</a></li><li><a class="nounderline abstract_t">Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:e1.</a></li><li><a class="nounderline abstract_t">Patterson R, Greenberger PA, Halwig JM, et al. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med 1986; 146:916.</a></li><li><a class="nounderline abstract_t">Agarwal R, Gupta D, Aggarwal AN, et al. Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India. Chest 2006; 130:442.</a></li><li><a class="nounderline abstract_t">Agarwal R, Aggarwal AN, Dhooria S, et al. A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J 2016; 47:490.</a></li><li><a class="nounderline abstract_t">Natarajan S, Subramanian P. Allergic bronchopulmonary aspergillosis: A clinical review of 24 patients: Are we right in frequent serologic monitoring? Ann Thorac Med 2014; 9:216.</a></li><li><a class="nounderline abstract_t">Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2004; :CD001108.</a></li><li><a class="nounderline abstract_t">Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 2013; 43:850.</a></li><li><a class="nounderline abstract_t">Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342:756.</a></li><li><a class="nounderline abstract_t">Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003; 111:952.</a></li><li><a class="nounderline abstract_t">Knutsen AP, Bush RK, Demain JG, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol 2012; 129:280.</a></li><li><a class="nounderline abstract_t">Gothe F, Schmautz A, Häusler K, et al. Treating Allergic Bronchopulmonary Aspergillosis with Short-Term Prednisone and Itraconazole in Cystic Fibrosis. J Allergy Clin Immunol Pract 2020; 8:2608.</a></li><li><a class="nounderline abstract_t">Pasqualotto AC, Powell G, Niven R, Denning DW. The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis. Respirology 2009; 14:1121.</a></li><li><a class="nounderline abstract_t">Salez F, Brichet A, Desurmont S, et al. Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis. Chest 1999; 116:1665.</a></li><li><a class="nounderline abstract_t">Agarwal R, Dhooria S, Singh Sehgal I, et al. A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma. Chest 2018; 153:656.</a></li><li><a class="nounderline abstract_t">Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001; 51:443.</a></li><li><a class="nounderline abstract_t">Varis T, Kaukonen KM, Kivistö KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998; 64:363.</a></li><li><a class="nounderline abstract_t">Bolland MJ, Bagg W, Thomas MG, et al. Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother 2004; 38:46.</a></li><li><a class="nounderline abstract_t">Woods DR, Arun CS, Corris PA, Perros P. Cushing's syndrome without excess cortisol. BMJ 2006; 332:469.</a></li><li><a class="nounderline abstract_t">Parmar JS, Howell T, Kelly J, Bilton D. Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax 2002; 57:749.</a></li><li><a class="nounderline abstract_t">Skov M, Main KM, Sillesen IB, et al. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J 2002; 20:127.</a></li><li><a class="nounderline abstract_t">Wong J, Black P. Acute adrenal insufficiency associated with high dose inhaled steroids. BMJ 1992; 304:1415.</a></li><li><a class="nounderline abstract_t">Erwin GE, Fitzgerald JE. Case report: allergic bronchopulmonary aspergillosis and allergic fungal sinusitis successfully treated with voriconazole. J Asthma 2007; 44:891.</a></li><li><a class="nounderline abstract_t">Glackin L, Leen G, Elnazir B, Greally P. Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Ir Med J 2009; 102:29.</a></li><li><a class="nounderline abstract_t">Chishimba L, Niven RM, Cooley J, Denning DW. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma 2012; 49:423.</a></li><li><a class="nounderline abstract_t">Agarwal R, Dhooria S, Sehgal IS, et al. A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J 2018; 52.</a></li><li><a class="nounderline abstract_t">Ricketti AJ, Greenberger PA, Patterson R. Serum IgE as an important aid in management of allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1984; 74:68.</a></li><li><a class="nounderline abstract_t">Agarwal R, Gupta D, Aggarwal AN, et al. Clinical significance of decline in serum IgE levels in allergic bronchopulmonary aspergillosis. Respir Med 2010; 104:204.</a></li><li><a class="nounderline abstract_t">Denning DW, Van Wye JE, Lewiston NJ, Stevens DA. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest 1991; 100:813.</a></li><li><a class="nounderline abstract_t">Marchant JL, Warner JO, Bush A. Rise in total IgE as an indicator of allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax 1994; 49:1002.</a></li><li><a class="nounderline abstract_t">Li JX, Fan LC, Li MH, et al. Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature. Respir Med 2017; 122:33.</a></li><li><a class="nounderline abstract_t">Jin M, Douglass JA, Elborn JS, et al. Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract 2023; 11:896.</a></li><li><a class="nounderline abstract_t">Voskamp AL, Gillman A, Symons K, et al. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract 2015; 3:192.</a></li><li><a class="nounderline abstract_t">Randhawa I, Chin T, Nussbaum E. Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach. J Asthma 2009; 46:445.</a></li><li><a class="nounderline abstract_t">Lin RY, Sethi S, Bhargave GA. Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab. J Asthma 2010; 47:942.</a></li><li><a class="nounderline abstract_t">Tillie-Leblond I, Germaud P, Leroyer C, et al. Allergic bronchopulmonary aspergillosis and omalizumab. Allergy 2011; 66:1254.</a></li><li><a class="nounderline abstract_t">Tanou K, Zintzaras E, Kaditis AG. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol 2014; 49:503.</a></li><li><a class="nounderline abstract_t">Jat KR, Walia DK, Khairwa A. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2018; 3:CD010288.</a></li><li><a class="nounderline abstract_t">Altman MC, Lenington J, Bronson S, Ayars AG. Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract 2017; 5:1137.</a></li><li><a class="nounderline abstract_t">Schleich F, Vaia ES, Pilette C, et al. Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature. J Allergy Clin Immunol Pract 2020; 8:2412.</a></li><li><a class="nounderline abstract_t">Tomomatsu K, Sugino Y, Okada N, et al. Rapid clearance of mepolizumab-resistant bronchial mucus plugs in allergic bronchopulmonary aspergillosis with benralizumab treatment. Allergol Int 2020; 69:636.</a></li><li><a class="nounderline abstract_t">Terashima T, Shinozaki T, Iwami E, et al. A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab. BMC Pulm Med 2018; 18:53.</a></li><li><a class="nounderline abstract_t">Tolebeyan A, Mohammadi O, Vaezi Z, Amini A. Mepolizumab as Possible Treatment for Allergic Bronchopulmonary Aspergillosis: A Review of Eight Cases. Cureus 2020; 12:e9684.</a></li><li><a class="nounderline abstract_t">Matsuura H, Fujiwara K, Omori H, et al. Successful Treatment with Benralizumab for Allergic Bronchopulmonary Aspergillosis That Developed after Disastrous Heavy Rainfall in Western Japan. Intern Med 2021; 60:1443.</a></li><li><a class="nounderline abstract_t">Dhariwal J, Hearn AP, Kavanagh JE, et al. Real-World Effectiveness of Anti-IL-5/5R Therapy in Severe Atopic Eosinophilic Asthma with Fungal Sensitization. J Allergy Clin Immunol Pract 2021; 9:2315.</a></li><li><a class="nounderline abstract_t">Ali M, Green O. Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis. Oxf Med Case Reports 2021; 2021:omaa029.</a></li><li><a class="nounderline abstract_t">Mikura S, Saraya T, Yoshida Y, et al. Successful Treatment of Mepolizumab- and Prednisolone-resistant Allergic Bronchopulmonary Aspergillosis with Dupilumab. Intern Med 2021; 60:2839.</a></li><li><a class="nounderline abstract_t">Lee TM, Greenberger PA, Patterson R, et al. Stage V (fibrotic) allergic bronchopulmonary aspergillosis. A review of 17 cases followed from diagnosis. Arch Intern Med 1987; 147:319.</a></li><li><a class="nounderline abstract_t">Moss RB. Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Curr Opin Pulm Med 2010; 16:598.</a></li><li><a class="nounderline abstract_t">Elphick HE, Southern KW. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2012; :CD002204.</a></li><li><a class="nounderline abstract_t">Nepomuceno IB, Esrig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Chest 1999; 115:364.</a></li><li><a class="nounderline abstract_t">Kraemer R, Deloséa N, Ballinari P, et al. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2006; 174:1211.</a></li><li><a class="nounderline abstract_t">Nové-Josserand R, Grard S, Auzou L, et al. Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients. Pediatr Pulmonol 2017; 52:190.</a></li><li><a class="nounderline abstract_t">Perisson C, Destruys L, Grenet D, et al. Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis. Respir Med 2017; 133:12.</a></li><li><a class="nounderline abstract_t">Poole CJ, Wong M. Allergic bronchopulmonary aspergillosis in garden waste (compost) collectors--occupational implications. Occup Med (Lond) 2013; 63:517.</a></li><li><a class="nounderline abstract_t">Allmers H, Huber H, Baur X. Two year follow-up of a garbage collector with allergic bronchopulmonary aspergillosis (ABPA). Am J Ind Med 2000; 37:438.</a></li><li><a class="nounderline abstract_t">Akiyama K, Takizawa H, Suzuki M, et al. Allergic bronchopulmonary aspergillosis due to Aspergillus oryzae. Chest 1987; 91:285.</a></li><li><a class="nounderline abstract_t">Mehta SK, Sandhu RS. Immunological significance of Aspergillus fumigatus in cane-sugar mills. Arch Environ Health 1983; 38:41.</a></li><li><a class="nounderline abstract_t">Godet C, Couturaud F, Marchand-Adam S, et al. Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial. Eur Respir J 2022; 59.</a></li><li><a class="nounderline abstract_t">Ram B, Aggarwal AN, Dhooria S, et al. A pilot randomized trial of nebulized amphotericin in patients with allergic bronchopulmonary aspergillosis. J Asthma 2016; 53:517.</a></li><li><a class="nounderline abstract_t">Vlahakis NE, Aksamit TR. Diagnosis and treatment of allergic bronchopulmonary aspergillosis. Mayo Clin Proc 2001; 76:930.</a></li><li><a class="nounderline abstract_t">Agarwal R, Garg M, Aggarwal AN, et al. Serologic allergic bronchopulmonary aspergillosis (ABPA-S): long-term outcomes. Respir Med 2012; 106:942.</a></li></ol></div><div id="topicVersionRevision">Topic 104431 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12417875" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15974818" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Allergic bronchopulmonary aspergillosis: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15969680" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19265090" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12975753" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3356845" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4950529" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Allergic broncho-pulmonary aspergillosis. Clinical immunology. 2. Skin, nasal and bronchial tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6697471" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Experience with allergic bronchopulmonary aspergillosis: some unusual features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4984426" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pulmonary allergic aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27365388" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3516103" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899843" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26585431" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25276240" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Allergic bronchopulmonary aspergillosis: A clinical review of 24 patients: Are we right in frequent serologic monitoring?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15266440" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Azoles for allergic bronchopulmonary aspergillosis associated with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23889240" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10717010" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12743557" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22284927" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fungi and allergic lower respiratory tract diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32147521" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treating Allergic Bronchopulmonary Aspergillosis with Short-Term Prednisone and Itraconazole in Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19909460" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10593792" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29331473" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422002" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9797792" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14742792" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16497762" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cushing's syndrome without excess cortisol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12149540" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12166560" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1628017" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acute adrenal insufficiency associated with high dose inhaled steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18097869" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Case report: allergic bronchopulmonary aspergillosis and allergic fungal sinusitis successfully treated with voriconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19284017" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22380765" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30049743" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6429230" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Serum IgE as an important aid in management of allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19800210" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical significance of decline in serum IgE levels in allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1653680" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7974292" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Rise in total IgE as an indicator of allergic bronchopulmonary aspergillosis in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27993289" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36581073" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25640470" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19544162" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20831464" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21517902" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Allergic bronchopulmonary aspergillosis and omalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24167019" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29551015" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28279664" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32268213" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mepolizumab for allergic bronchopulmonary aspergillosis: Report of 20 cases from the Belgian Severe Asthma Registry and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32247541" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Rapid clearance of mepolizumab-resistant bronchial mucus plugs in allergic bronchopulmonary aspergillosis with benralizumab treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29587693" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32923277" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Mepolizumab as Possible Treatment for Allergic Bronchopulmonary Aspergillosis: A Review of Eight Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33191330" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Successful Treatment with Benralizumab for Allergic Bronchopulmonary Aspergillosis That Developed after Disastrous Heavy Rainfall in Western Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33689868" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Real-World Effectiveness of Anti-IL-5/5R Therapy in Severe Atopic Eosinophilic Asthma with Fungal Sensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33948179" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33642487" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Successful Treatment of Mepolizumab- and Prednisolone-resistant Allergic Bronchopulmonary Aspergillosis with Dupilumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3545117" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Stage V (fibrotic) allergic bronchopulmonary aspergillosis. A review of 17 cases followed from diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20720494" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22696329" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027433" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16959918" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27717223" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29173443" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23975883" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Allergic bronchopulmonary aspergillosis in garden waste (compost) collectors--occupational implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706756" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Two year follow-up of a garbage collector with allergic bronchopulmonary aspergillosis (ABPA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2433099" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Allergic bronchopulmonary aspergillosis due to Aspergillus oryzae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6338838" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Immunological significance of Aspergillus fumigatus in cane-sugar mills.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34764182" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26666774" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A pilot randomized trial of nebulized amphotericin in patients with allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560305" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Diagnosis and treatment of allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22445696" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Serologic allergic bronchopulmonary aspergillosis (ABPA-S): long-term outcomes.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
